Type 2 & other diabetes

Relationships among Helicobacter pylori seropositivity, the triglyceride-glucose index, and cardiovascular disease: a cohort study using the National Health and Nutrition Examination Survey (NHANES) database

Cardiovasc DiabetolPublished Cross-sectional and cohort study

Authors' conclusion

H. pylori seropositivity may indirectly elevate the risk of CVD and mortality via the TGI. Combining the patient's H. pylori serological status with their TGI could enhance the predictive ability for CVD occurrence and related mortality. Therefore, the clinical practice of screening for and eradicating H. pylori in CVD patients may be anticipated.

Study context

Population
NHANES participants; 4,488 (47.75%) H. pylori-IgG-positive, 3,934 (41.86%) with cardiovascular diseases (CVD)
Participants
9,399 participants
Exposure
H. pylori seropositivity and triglyceride-glucose index (TGI) vs lower TGI/seronegativity
Outcome
Risk of CVD (logistic regression) and all-cause mortality (Cox model)
Methodological detailsNHANES III (1988-1994) and NHANES (1999-2000), logistic regression, Cox proportional hazards model, restricted cubic spline, mediation analyses
  • NHANES III (1988-1994) and NHANES (1999-2000)
  • Logistic regression
  • Cox proportional hazards model
  • Restricted cubic spline
  • Mediation analyses

Main finding

As reported in the abstract

CVD risk, general population

TGI ≥75th percentile & H. pylori-IgG-positive: highest CVD risk, OR

1.487

95% CI 1.088–2.033

Observational data: associations, not effects.

Further findings

All-cause mortality among patients with CVD

TGI ≥75th percentile & H. pylori-IgG-positive: higher all-cause mortality (ACM) risk, HR
1.227 (95% CI 1.009-1.491)

Mediation via TGI

Significant mediating effect of H. pylori via TGI on CVD occurrence
Pindir = 0.004
Significant mediating effect of H. pylori via TGI on mortality
Pindir = 0.004

Original publication

Relationships among Helicobacter pylori seropositivity, the triglyceride-glucose index, and cardiovascular disease: a cohort study using the NHANES database. Cardiovasc Diabetol. Published 18 December 2024. doi:10.1186/s12933-024-02536-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.